Structured evidence table for Green Tea Extract Cardiometabolic Markers Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Green Tea Extract Cardiometabolic Markers Randomized Trial | The current systematic review and meta-analysis study aimed to establish the effects of green tea supplementation on cardiovascular risk factors including lipid profile, blood pressure, glycemic control markers and CRP. | 1 | Zamani M (2023) | The effects of green tea supplementation on cardiovascular risk factors: A systematic review and meta-analysis. |
| Green Tea Extract Cardiometabolic Markers Randomized Trial | Methods A systematic literature search of randomized clinical trials (RCTs) that investigated the effects of green tea supplementation and cardiovascular risk factors was undertaken in online databases including PubMed/Medline, Scopus, Web of Science, and Embase using a combination of green tea and cardiovascular risk factors search terms. | 1 | Zamani M (2023) | The effects of green tea supplementation on cardiovascular risk factors: A systematic review and meta-analysis. |
| Green Tea Extract Cardiometabolic Markers Randomized Trial | Results from the random effects meta-analysis showed that GTE supplementation significantly reduced TC (WMD = -7.62; 95% CI: -10.51, -4.73; P = P = P = P = 0.008), DBP (WMD = -0.87; 95% CI: -1.45, -0.29; P = 0.003), while increasing HDL-C (WMD = 1.85; 95% CI: 0.87, 2.84; P = 0.010). | 1 | Zamani M (2023) | The effects of green tea supplementation on cardiovascular risk factors: A systematic review and meta-analysis. |
| Green Tea Extract Cardiometabolic Markers Randomized Trial | Purpose A bulk of observational studies have revealed the protective role of green tea supplementation in cardiovascular diseases. | 1 | Zamani M (2023) | The effects of green tea supplementation on cardiovascular risk factors: A systematic review and meta-analysis. |
| Green Tea Extract Cardiometabolic Markers Randomized Trial | 1 Metabolic syndrome (MetS) is a multifactorial disorder characterized by a cluster of metabolic and cardiovascular abnormalities, including central obesity, dyslipidemia, insulin resistance, and hypertension, which collectively increase the risk of suffering from metabolic diseases such as type 2 diabetes and cardiovascular diseases in the long term []. | 4 | de la Fuente-Muñoz Mario (2026) | Enhanced Effects of Complex Tea Extract and the Postbiotic BPL1 ® HT on Ameliorating the Cardiometabolic Alterations Associated with Metabolic Syndrome in Mice |
| Green Tea Extract Cardiometabolic Markers Randomized Trial | Impairment at any step, such as decreased IRS phosphorylation or PI3K/Akt activity, leads to defective glucose transport, reduced glycogen synthesis, increased lipolysis, and the development of insulin resistance []. | 4 | de la Fuente-Muñoz Mario (2026) | Enhanced Effects of Complex Tea Extract and the Postbiotic BPL1 ® HT on Ameliorating the Cardiometabolic Alterations Associated with Metabolic Syndrome in Mice |
| Green Tea Extract Cardiometabolic Markers Randomized Trial | 6 7 8 9 10 11 One of the most important factors contributing to the development of insulin resistance is increased adiposity, and particularly visceral adiposity [], a condition that is present in most patients with MetS []. | 4 | de la Fuente-Muñoz Mario (2026) | Enhanced Effects of Complex Tea Extract and the Postbiotic BPL1 ® HT on Ameliorating the Cardiometabolic Alterations Associated with Metabolic Syndrome in Mice |
| Green Tea Extract Cardiometabolic Markers Randomized Trial | 2 3 4 5 Central to the pathogenesis of MetS is insulin resistance, a condition characterized by the disruption of the phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) signaling pathway, a critical mediator of insulin’s metabolic actions in key metabolic tissues such as liver, muscle, and adipose tissue [,]. | 4 | de la Fuente-Muñoz Mario (2026) | Enhanced Effects of Complex Tea Extract and the Postbiotic BPL1 ® HT on Ameliorating the Cardiometabolic Alterations Associated with Metabolic Syndrome in Mice |
Source documents